Tags Posts tagged with "weed"

weed

4 9671

By Jason Spatafora @WolfofWeedSt

“I fear the Greeks, even those bearing gifts.”- Virgil

The DEA’s recent cannabis research expansion is a Harry Houdini inspired smoke show of misdirection all to set up the next trick; there I said it. While some view it as a positive first step, I tend to think it served a very deliberate function. Optically it played directly into expected vitriolic fallout from advocates, activists and media touts, all of which lined up to ignite their “DEA should reschedule cannabis” torches. In a “perfect world” scenario these people aren’t wrong, cannabis isn’t Heroin’s equal & 1+1=2, but just as fire cannot exist in a vacuum, neither can a rational cannabis debate. And while everyone on the side of reason is shouting in unison about rescheduling they failed to see that they might have just had their pockets picked. DEA’s policy statement that everyone seemed to ignore there are 33 words that have the potential to create the legal framework for the monopolization of Cannabis by means of an exclusionary application process.

Prologue – August 10th, 2016

Russ Baer, a staff coordinator for the Drug Enforcement Administration (DEA) media affairs wing gave a response to Steven Nelson of USNEWS.com via email. Nelson later shared a screen grab of the email via tweet. The statement made to him from this Drug Enforcement Administration staff coordinator read:

“Tomorrow morning (August 11th, 2016) the Drug Enforcement Administration will be making some important announcement regarding Marijuana related topics that will be published in the Federal Register. Because of your interest and/or prior engagement with the DEA on this subject, the DEA office of National Media Affairs is reaching out to you regarding these anticipated announcements.”

Over the next 24 hours social media was a blaze, with many people within the industry uncovering the fact that Rescheduling wouldn’t happen and that the DEA response would have to do with research. As expected, the incendiary scheduling of cannabis debate raged on into the following day.

August 11th, 2016

As expected, the Drug Enforcement Administration disappointed the advocates and activists of medical marijuana by not removing or rescheduling marijuana from its class 1 controlled substance status. Yet the DEA, in all of its benevolence, offered a consolation prize of sorts, by “deciding” to expand the study of Medical Marijuana for researchers, Universities & drug companies outside of the confines of a single federally legal facility. The facility, to refresh your memory is located at the University of Mississippi, (ranked 164th in Bio Sciences) and had up to this point been the sole research monopoly on legally grown marijuana, courtesy of the NIDA (National Institute on Drug Abuse).

DEA’s Misdirection Strategy

Over the next few days it seemed that every headline following the DEA’s deliberation was about the archaic rescheduling system & how cannabis is safer statistically than opiates that are schedule 2. Some media outlets went as far as to paint a “glass half full” picture. The LA Times for example did a piece titled “DEA ends its monopoly on marijuana growing for medical research.” The social reaction from cannabis enthusiasts, advocates and potrepreneurs from Main Street to Wall Street was as expected with everyone chiming in on social media to wag their fingers at the DEA. Representative Barbara Lee, a congresswoman from Oakland California stating via tweet “Politicians aren’t doctors or scientists. Marijuana research prohibitions are outdated, unscientific, & dangerous for those who need #MMJ.” As expected the rhetoric from the cannabis side was “The DEA is bad, the War on Drugs is a complete failure, Big Pharma is to blame,” so on and so forth.

IMG_8473

The people aren’t wrong on many of these points. The War in Drugs is a failure when considering addiction has been plateauing since its 1970 inception and US drug control spending is up 2000%, which to date stands at $1.5 trillion dollars. We can go on and on as to where that money went, what industries it created (prison industrial complex), the people it disproportionately targeted (minorities), but that’s a whole other article or book for that matter. Big Pharma however does have its trillion dollars hands in this story, but more on that later as I’ve digressed.

Not to go back and pick on the LA Times click-bate headline of “DEA ends its monopoly on marijuana growing for medical research,” but did it really end the monopoly? Let’s evaluate the idea. Yes, a monopoly is defined as “the exclusive possession or control of the supply or trade in a commodity or service.” The University of Mississippi was in fact in exclusive possession of the NIDA edict to legally grow marijuana and study it. On the surface the Monopoly has ended, but the reality is that we are just switching out the term Monopoly for an Oligarchy. Is an oligarchy any different than a monopoly in the sense that it’s just a smaller group carving out the biggest slices for themselves, eliminating competition by means of out maneuvering or outspending their opponent in an effort to influence policy such as this? Consider that the biggest lobby against the cannabis Industry is the pharmaceutical industry, yet they’re simultaneously studying cannabis for the purpose of synthesizing its many chemical compounds to create their high margin drugs.

Currently, their high margin bread and butter are the opioids for pain management such as OxyContin, Percocet and their generic versions of each. The drug companies are experts at isolating molecules from nature to create drugs that cost pennies to manufactures. In a zero sum game, cannabis is a direct threat to pharma companies, by snatching billions in profit and simultaneously causing billions in losses. Anti-cannabis lobbies would also be at risk as the pharmaceutical giants that feed them down on K Street would lose out on easy paydays. These anti-Marijuana lobbyists provide a micro look at the systemic problems within American politics illustrating how/why elected officials in Congress consistently vote against the interests of their collective constituency and bring forth carefully crafted bills or amendments like this one.

On the DEA’s policy statement and legal considerations section, under, legal applicable considerations it states.

“Second, as with any application submitted pursuant to section 823(a), in determining whether the proposed registrationwould be consistent with the public interest, among the factorsto be considered are whether the applicant has previous experience handling controlled substances in a lawful manner and whether the applicant has engaged in illegal activity involving controlled substances. In this context, illegal activity includes any activity in violation of the CSA (regardless of whether such activity is permissible under State law) as well as activity in violation of State or local law. While past illegal conduct involving controlled substances does not automatically disqualify an applicant, it may weigh heavily against granting the registration.”

Translation, grow marijuana even in a state where it’s legal and you are going to have a hard time becoming a manufacturer or researcher for the DEA’s new policy, thus excluding tier one cultivators in practice and likely creating a perpetual home for cannabis on the scheduling list. Prohibition’s end could very well be right around the corner, but the fear is in the form of legal medical marijuana at a Walgreens near you. I asked the DEA’s Russ Baer directly if the inserted language above in bold would be a non-starter for current cultivators wanting to become manufacturers as they are in clear Violation of CSA? In a written statement to Marijuana Stocks the DEA’s official response was:

“DEA is serious about facilitating marijuana research and that there is a lawful pathway for doing so. This DEA decision will facilitate increased research involving marijuana, within the framework of the law and U.S. treaty obligations, to enhance the drug’s supply available to researchers. The goal of this historic and monumental policy shift is to increase the amount and variety of marijuana available to researchers and make it easier for researchers to obtain marijuana as compared to current system under which marijuana must be obtained from NIDA. Growers must become registered with DEA, following the submission of an application, which DEA will evaluate in accordance with the CSA. Registered growers will need to comply with all CSA regulatory requirements, such as quotas, record keeping, order forms, and maintenance of control against diversion. Marijuana produced under this proposal may only be supplied to DEA-registered manufacturers and researchers, and only for purposes authorized by the CSA.

All potential new drugs, including drug products made from marijuana, are subject to the rigors of the drug approval process mandated by the Federal Food, Drug and Cosmetic Act (FDCA). This drug approval process requires that before a new drug is allowed to enter the U.S. market, it must be demonstrated through sound clinical trials to be both safe and effective for its intended uses,” stated Russ Baer of the Drug Enforcement Agency.

When asked if the inserted language also creates an unfair advantage for Pharma companies the response from the Drug Enforcement Administration circled back to the CSA (Controlled Substance Act) stating that the “DEA has adopted a new policy, consistent with the CSA and U.S. treaty obligations, under which additional entities may become registered with DEA to grow and distribute marijuana for research purposes. DEA will evaluate each application it receives to determine whether adding such applicant to the list of registered growers is necessary to provide an adequate and uninterrupted supply of marijuana to researchers in the U.S. In addition, applicants must demonstrate their ability to safely secure the drugs to prevent diversion, while abiding by the approved research protocol.”

The Controlled Substance Act

Everything points back to the Controlled Substance Act, a bill that was introduced into the Congress by Harley Staggers and took less than 6 weeks to get passed by the Senate and signed into law by President Richard M. Nixon. The signing of this document not only created the “War on Drugs,” but put an enforcement agency (DEA) in charge of Cannabis scheduling, circumventing the FDA in a move that creates an inter-agency firewall of sorts. The DEA’s position on why the FDA, who already regulates pharmaceutical drugs, isn’t in charge of marijuana rescheduling was point blank, “The Controlled Substances Act provides a mechanism for substances to be controlled (added to or transferred between schedules) or decontrolled (removed from control). The CSA provides roles for DEA and the FDA. Proceedings to add, delete, or change the schedule of a drug or other substance may be initiated by DEA, HHS, or by petition from any interested party. Once initiated, the process involves a deliberate and collaborative interagency exchange.”

IMG_8472

In Laymen’s terms CSA effectively says “DEA you’re in charge of this, FDA you’re in charge of that.” Unfortunately, Marijuana will never be completely removed from the scheduling list unless there is a major political overhaul in every branch of government, if and only if elected officials stop letting lobbies pour honey in their ears and money into campaigns. The reality from my perspective is that the DEA is a scapegoat, the perfect Boogey Man, simply because their job is to follow orders. They are soldiers in a sense, adhering to the guidelines of the Controlled Substance Act (CSA), a legal document crafted by a congress, molded in the image of benefactors, used to fuel a fake war and create cottage industries.

The DEA knows marijuana is safer than Oxy and that’s not speculation that’s a direct quote. They don’t want to go after the mother transporting medication to her sick child because they’re suffering from seizures. They want the dangerous individuals like El Chapo or the pill mills slinging Oxy off the streets. They have no interest in going after all cultivators following state law to the letter. Are there exceptions, of course! Does it make these comments directly from them any less true? No.
DEA’s direct position on which drug is more dangerous from a consumption standpoint as it relates to Cannabis vs OxyContin? “There were more than 47,000 drug overdose deaths in 2014, or approximately 129 per day, more than half (61 percent) of which involved either a prescription opioid or heroin. Marijuana meets the statuary criteria of a Scheduled I controlled substance, and has been determined to have a high abuse potential with no currently accepted medical use. Schedule I includes some substances that are exceptionally dangerous (including heroin and LSD) and some that are less dangerous (including marijuana, which is less dangerous than some substances in other schedules).” When asked point blank, what’s more dangerous Oxy or Marijuana DEA says “Oxy.”

Robert Capecchi, Director of Federal Lobbying at the Marijuana Policy views medical marijuana legalization as a means to an opioid end as well as fiscal no brainer with far reaching benefits.

“Ending marijuana prohibition will allow licensed businesses to cultivate, distribute, and sell marijuana to adults. Unlike the criminal market, a legal and regulated market means products are pure, tested and labeled, sales are taxed, and business disputes are resolved in the courts, not with violence. Additionally, there is promising evidence to suggest that legal access to medical marijuana reduces the rates of opioid overdoses and the reliance on prescription pain killers.”

Foregone Conclusion?

Prohibition’s end could very well be right around the corner, but would we want it in the form of legal medical marijuana at a Walgreens near you? August 11th’s ruling was either one of many dominos in the quest for the monopolization of cannabis or just a pessimistic idea based off of history repeating itself. Regardless of which reality we are presently in, it doesn’t hurt to try and connect the dots, but if I can leave you with one last thing it’s the number 6630507. In case you’re wondering that’s the United States patent # they filed for cannabis in 2003 citing “multiple therapeutic uses.” I can only postulate why they did that….

Regards,

Jason Spatafora

Drug War

Medical Marijuana Shows Parkinson’s Patient Some Relief

Ian Frizell, age 55, was diagnosed with Parkinson’ disease in 2011. He has suffered from symptoms since 1995, which continually got worse over time. Ian has filmed a video to display what a significant difference a small amount of medical marijuana makes to his tremors. In the clip, he states that he recently underwent deep brain stimulation surgery, a medical implant that helps hide the effects of Parkinson’s. He switches the DBS device off to show the seriousness of his tremors.

 


Click Here To View Full Article


 

Research Reveals Some Of Marijuana’s Health Effects

 

It may essentially help some people sleep and ease chronic pain, but it is also possible to heighten the danger of triggering a heart attack or develop schizophrenia. A Federal advisory panel came to those those conclusions about cannabis in a recent report.

The analysts also called for a…


Click Here To View Full Article


 

Vitality Biopharma (VBIO)

 

Vitality Biopharma (VBIO) has been in our spotlight for the better part of the last few weeks and we’ve seen this cannabis biotech deliver real potential for gains. What started out as a $0.98 alert ended up turning into a $4.24 bull. Even after pulling into $1.93, VBIO managed several clear bounces. This will be something we’ll be continuing to monitor into the later half of the month as well. If you haven’t taken a look at this company yet, check out our full report via the link below.


Click Here To View Full VBIO Report


 

 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

1 2818

Biotech Buzz Could Focus On Cannabis

San Francisco will be a hotbed for biotechnology this week. The annual JPMorgan Healthcare Conference kicks off on Monday the 9th and goes through Thursday the 12th. But this isn’t the only conference and there will surely be thousands of investors in the city to attend all kinds of presentations being made, which are focused on biotechnology & healthcare. Outside of just JPM’s conference, the crowd around Union Square also consists of the Biotech Showcase, which sets up at the Hilton San Francisco Union Square; and the OneMedForum across Post Street from the St. Francis.

Biotech_Showcase

There’s also the StartUp Health Festival on Montgomery Street and other conferences. Considering that thousands of people who aren’t going to invitation-only conferences like JPM, it would stand to reason that attention will be on the industry in full force this week.

Recently Vitality Biopharma (VBIO) announced that it would be presenting at the Biotech Showcase on Wednesday January 11th. The Showcase hosts over 2,800 attendees, over 5,600 one-on-one meetings, and will be expecting to see over 550 investors present.

Biotech Showcase™ is an investor and networking conference working to provide private and public biotech and life sciences companies with an opportunity to present to, and engage with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this week, which is widely viewed as setting the tone for the coming year…so JPMorgan is just the tip of the iceberg during San Fran’s biotech invasion.

“Biotech has historically outperformed the broader market during The J.P. Morgan Healthcare Conference,” biotech analysts at the firm wrote in a note to clients ahead of the event.

And we aren’t the only ones who could be seeing the potential “writing on the wall.” One of the presenters at the conference has even said, “…there’s a growing interest in medical cannabis among traditional health care institutions. This is a growing part of what is becoming mainstream health care.” As we said last week, even though we focus specifically on marijuana stocks, the biotech aspect of VBIO could be something to pay attention to heading into this week, considering the historic impact that the JPM conference (starts today) has had in the past for companies that have a stake in the space.

We said that this week could shed some light on many biotech companies including those involved with cannabis. Now we see that VBIO will be at ground zero, not just as another biotech company that could benefit from the shockwave but management will be in the exact location and presenting to the exact audiences.

Company CEO Robert Brooke will provide a 30-minute overview of Vitality Biopharma’s business during his presentation and will be available to participate in one-on-one meetings with registered attendees.

Event: Biotech Showcase Conference
Date: Wednesday, January 11, 2017
Time: 8:00 a.m. PT
Track: Room 8 (Ballroom Level)
Location: Hilton San Francisco Union Square, San Francisco, CA


 

 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 814

 

Vitality Biopharma ($VBIO)’s 3-Day Rally Set To Continue?

Vitality Biopharma (VBIO) saw a very strong run during most of December. When we first began to pick up coverage it was sitting around $0.98 and during the course of the weeks to follow, we watched as VBIO ran to highs of $4.23. Despite the fact that many thought the excitement was over when VBIO pulled back, we’ve now seen it breakout once again. In fact since bottoming at $1.93 last week, VBIO has maintained a 3 day run that has taken it back to highs of $3.22 yesterday; a 67% rebound.

We said it late last year and the sentiment continues to hold up so far in 2017: Canna-biotech companies have begun to catch much more attention; biotech over all has begun to see an increase in activity following President Elect Trump coming into the spotlight. In an interview with Ken Kam of Forbes, Todd Hagopian said, “After underperforming the S&P 500 by over 30% in the past 14 months, there is plenty of room for this sector to run. In fact, the S&P 500 Biotechs are trading at a Forward P/E of just 22.4% vs. Consumer Staples who are trading at a Forward P/E of 17.2%. This is pretty remarkable, considering that the same group of Biotech companies have a short term earnings growth rate of 17.3%, versus the Consumer Staple companies who are projected to grow at just 8.0%. Basically, this data would seem to suggest that either there is a huge bubble in Consumer Staples stocks, or the Biotechnology market is about to double.”

Vitality’s preclinical studies for its proprietary prodrugs of CBD and THC were recetnly reviewed and approved by the U.S. FDA. So, if is your first time seeing VBIO, we’ve got a full report you can access before the opening bell today.

 


Click Here To View Full VBIO Report



The Hero of HOLLYWEED

 

In case you missed it this New Years the citizens and tourists got a wonderful welcome when they looked up at Mount Lee in HollyWood, or should we say “HOLLYWEED!” The Iconic Hollywood sign was given a hilarious, yet impactful redesign given that the state of California now has recreational marijuana after a November 8th vote in favor of the law change by its illustrious citizens.

 


Click Here To View Full Article


 

Senator Warren Is Working on Getting Banks To Do Business With The Marijuana Industry

As marijuana shops start to sprout and grow within states that have legalized the drug, they face a critical stumbling road block – lack of access to the kind of routine banking services other businesses take for granted. U.S. Sen. Elizabeth Warren, a Massachusetts Democrat, is making a solid attempt at making an effort to ensure vendors working with legal marijuana businesses, from chemists who test marijuana for harmful substances to firms that provide security, don’t have their banking services taken away.


Click Here To View Full Article



Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

1 6230

HENDERSON, NV–(Marketwired – Oct 24, 2016) – MCIG, Inc., ( OTCQB : MCIG ) a diversified company servicing the legal cannabis, hemp, and CBD markets is pleased to give this corporate update to our current & future shareholders surrounding the operations of MCIG, Inc. First, let me thank the many investor emails I have received over the past few weeks that have made inquiries as to our product lines as well as our Nevada operations, it is for this reason I am providing this update ahead of what we feel is a pivotal moment for the cannabis industry.

The 2016 elections and cannabis related ballots across the United States are exceptionally important to the continued expansion of the industry and we feel MCIG, Inc. is well positioned at many different market verticals, most notable the Nevada cultivation market. Company divisions are fundamentally healthy and we expect to see revenues continues to grow as overall operations expand and are scaled to meet various forms of demand. Currently, 3 of our 4 divisions are profitable as we continue to focus on this profitability via cost cutting initiatives that continue to improve our margins. Also, our cash position has significantly improved while our expenses remain at all-time lows allowing for a good base for future growth.

MCIG continues to expand our shareholders position within the rapidly growing Cannabis market and we have become even more geographically diverse following the addition of new clients, new products roll outs, and continued market penetration via existing product lines and expanded distribution agreements.

In an effort to keep our investors up to date with everything going on within the company, we want to provide this update for each of our portfolio companies and investments as we prepare to enter into the third quarter.

Scalable Solutions -
After being established in March 2016, Scalable Solutions has quickly become a leader when it comes to Marijuana cultivation construction. Currently, we have five projects under construction and a backlog of more than $6 million dollars. Scalable Solutions will become a main driver of revenues for mCig as the legal cannabis industry continues to grow within its Nevada, which is expected to be a $629.5 million market by 2020. The company is also currently working on smaller projects in Washington and Oregon in various capacities while expanding its base of operation in Nevada.

It is important to note that if Nevada legalizes adult use cannabis on November 8, 2016 we will witness an unprecedented socio-economic impact in a state already shaped and fueled by tourism and entertainment. . That’s why we are taking an aggressive approach to contract new projects in Nevada while expanding our professional team of engineers and consultants.

Currently, Scalable’s Sin City and Green Leaf Farms projects under contract are ahead of schedule. Both projects will be expanding as the Nevada markets expand to fulfill their eventual maximum space usage for the large land and warehouse they respectively occupy. Sin City will eventually expand from 4,800 square feet to 40,000 square feet and Green Leaf will modify it entire facility in order to occupy all 30,000 square feet of their facility.

Management expects the Solaris project will become the model for future Green Houses which when completed will be the largest approved green house facility in Nevada with room to grow. The current parcel of Land that Solaris occupies is 12 acres, with only 20% currently allocated by the main Solaris Greenhouse. Many licensed producers are planning on scaling their operations as demand increases as it has increased in other markets. Our scalable division has already seen our current projects swell in size and each of our current clients has expanded the construction budgets multiple times, giving MCIG Inc. via Scalable Solutions years of continued project revenue.

Scalable targets a 10% profit margin on its construction, with monthly management fees and performance incentives. This continued growth along with identifying other avenues for revenues and expansion will ensure Scalable’s long term viability.

VitaCig Brand
The sale of our flagship VITACIG Brand just had a record breaking quarter as VitaCig continues to expand its operations outside of the united states. VitaCig will soon debut in the Philippines, South Africa, and Hungary. With the recent country additions, VitaCig now exports its product to more than 30 different countries.

Part of that success, is due to our R&D department, who continues to develop the world’s most innovative, and unique inhalation technologies and formulas. Within the last few month, VitaCig has released four new concept flavors under the, S-Edition. This Special Line Edition features SURGE B-12 + Energy Complex, SLEEP VitaCig® Edition, Kama Sutra (SEX), STRESS VitaCig® Edition, with 100% real Cocoa, Getting into the Holiday spirit early, VitaCig has just released its VitaCig Candy Cane — Holiday Limited Edition, the perfect gift or stocking stuffer for this Holiday season. Orders can be placed by visiting: http://www.vitacig.org/

VitaCBD Brand
At the CHAMPS Tradeshow in Denver, Sept. 26-28, 2016 the Company launched its new and improved VitaCBD™ Product Line to Buyer’s in the Smoke Shop Industry.

The new line consists of healthy, uniquely blended 250mg, 500mg and 1000mg tinctures… 150mg and 300mg PG Free E-Liquid… 100mg, 500mg and 1000mg Blood Orange Essential Oil Infused Topical Lotion, a complete line of relaxing melatonin and 25mg CBD Edibles, with more in the works.

The CBD Division has begun supplying Raw Hemp-Extracts to other CBD Manufacturing Companies as Cherry Hemp Oil Bulk CBD Supply Co. During its initial two week period of operations the CBD Division logged over $50,000 in sales.

With numerous Distribution Networks with their eye on VitaCBD™, a new Bulk CBD Supply Co., a heavy on-line presence, along with plans for unique, Hemp-Extract Based consumer product development phases, future growth for this new CBD Division should become a significant boost for mCig, Inc. as a whole. Orders can be placed by visiting: http://www.vitacbd.com

Rollies Division -
MCIG’s Rollies division recently entered into a partnership agreement with Nevada based company Vellum LLC. Both companies will work together on bringing to the market a new format of smoking papers and cannabis pre-roll filling services to a different marijuana businesses.

Vellum LLC provides pre-roll filling services for two California brand’s: Nativ and “Lucy’s” using a new JOINT format from MCIG. Collaboration of two companies, already generated more than 1 mil pre-rolled sold.

“MCIG’s Rollies division is finally on a roll”, says Alex Levitsky the CEO of Rollies. During the past 5 months we have been researching and testing Nevada’s marijuana market. We have met with many owners and managers of cannabis cultivation, production and dispensaries businesses. They all were highly impressed with our unique format of pre-rolls. Success of “Nativ” and “Lucy’s” have spiked tremendous interest from Las Vegas cannabis businesses. We’re in the middle of making a deal with a big cultivator/producer in Las Vegas which will significantly increase our sales volume on papers as well as filling services performed. Now, with joining forces of an experienced management team form Vellum, we would be able to expand our services rapidly to all marijuana legal states across an America.

mCig Internet
The company oversees all retail sales of mCig’s products. In May 2016, MCIG developed and approved a multifaceted operational plan for the expansion of its retail sales. The strategy has resulted in significant growth and is based upon these principles:

1. Expand domain name and website presence to capture and use to the Company’s advantage the recent and consistent changes in the Google ranking process, seeking guidance and direction from the industry experts and market leaders.

2. Develop and implement internally and externally, a system in which sales to customers can be expedited with secure privacy, yet inherent transparency.

3. Expand product sales to include not just our own proprietary products, but to be the industry leader in CBD sales.

Based upon this research, the Company acquired three specific domain names to use in conjunction with the four domain names it operates. As part of these acquisitions we have some of the best site development, SEO, and analyst in the market available to us who have provided in depth and thorough analysis of all out sites.

With the goal to propel mCig Internet towards domination of the specific industry keywords organically, and not by the conventional paid advertising methods that often prove highly ineffective, mCig Internet strives to control the primary keyword positions, and once achieve, to maintain them, at no additional costs unlike our various competitors.

Additional Updates
Omni Health, Inc. — While not recorded on the financial statements of MCIG, the Company maintains approximately a 9% interest in the company. Omni Health is the manufacturer and distributor of anti-aging creams and operates a Pharmacy operation in the Miami, Florida area.

Omni Health is conservatively projecting $6M in revenue with an 8% net profit margin for FY 2017. Omni will be more active independently promoting their company as soon as the symbol change is approved, any day now. Realizing value for our shareholders is a must and we have great plans for our position in Omni for our shareholders.

Conclusion

All in all, as previously stated, we feel we have created an environment where our company is a bright spot for the ancillary cannabis and hemp markets. MCIG has clearly reached an important inflection point of controlled expenses, rising revenues, and profitability. While the road was long we chose it not because it was easy, but because it was difficult and shareholder friendly. MCIG’s fiscal prudence and the avoidance of toxic debt is what has allowed us to be a diversified investment rather than a fly by night company trying to get it right at the cost of its shareholders. We are poised to flourish, rather than to fade and our corporate philosophy will continue to remain intact for the benefit of our shareholders. The recent retirement of 50,000,000 shares of stock is further testament to this fact and we will be announcing more changes to benefit shareholders as well as update shareholders to the potential impact of the November 8th ballot initiative impact, which we feel one way or another is either good news or great news for MCIG Inc. Thank you for your time.

Regards,
Paul Rosenberg
CEO MCIG Inc.

About mCig, Inc.
Headquartered in Henderson, Nevada, mCig Inc. ( OTCQB : MCIG ) A diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. MCIG has transitioned from a vaporizer manufacturer to industry leading large scale, full service cannabis cultivation construction company with its Scalable Solutions division currently operating in the rapidly expanding Nevada market. The company looks forward to growing its core competencies to service the Ancillary legal Cannabis, Hemp and CBD markets, with broader expansion to take place once federal laws change. For more information visit www.mcig.org.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

    0 7204

    Has Smoked WEED!!!

    hqdefault

    Michael Phelps, who is unarguably the greatest Olympian of all time (The #GOAT) has smoked marijuana. At the age of fifteen at the 2000 Athens Olympics, Phelps became the youngest male to make an Olympic swim team in almost seven decades. While he did not win at that time, he did place in the finals. During the world championship the next year, however, Phelps, still fifteen, became the youngest male ever to set a swimming world record. He then proceeded to break that record again and become the world champion.

    He continued to win world championships up until the 2004 Olympic Games, but it did not stop there. Phelps went on to break two world records during this period and won a grand total of six gold medals. The next Olympic Games Phelps was even more successful, setting seven new world records and winning a total of eight gold medals, beating Mark Spitz record of seven gold medals won in a single Olympic games.

    The following year the world was shocked to hear Michael Phelps, Wheaties cover boy did something no 20-year-old Olympian should ever do. Phelps made headlines when a picture of him surfaced with him taking a Bong Rip. To be fair, it wasn’t even a big bong and a guy like him can definitely clear a much bigger chamber with his superior lung capacity. Even so, he was under fire by moms & dads that felt this kid smoked weed. The Kellogg Company refused to be his sponsor and USA Swimming gave him a three-month suspension swimming ban. Phelps publicly apologize and was forced to admit to “inappropriate.” Should Phelps have apologized for being a kid that couldn’t legally buy beer just because a few companies said he disappointed children that held him up as a role model? Hell NO!

    If you’ve followed the news the last two days, the DEA just announced that they are unwillingly to reschedule marijuana and keep it as a class 1 drug. As a class one drug, according to the DEA Marijuana is more dangerous & addictive than Cocaine, Oxycontin and amphetamines. Yet here we have Phelps the greatest Olympic athlete of all time still winning gold at the Rio Olympics and probably still smoking weed in the off season. Phelps is proof of just how innocuous marijuana can be. Those against marijuana prohibition will state that the drug will ruin your life, make you lazy, etc. Michael Phelps destroys that argument by being the most decorated Olympian of all time with twenty-one (and counting) gold medals!

    It actually turns out that the masterminds behind the Olympics were under the same impression; in 2013, the World Anti-Doping Agency (WADA) changed their rules concerning marijuana. No one was really paying attention when they made this rule change because they were focusing on the banned substances being added. In 2016 the limit of THC in your system was moved to 150 ng/ml. Basically that means you can’t show up stoned when competing, drunk or hungover. Theoretically you can smoke a month before you compete and be a-ok.

    Congratulations Michael Phelps on being the most decorated athlete in Olympic history and being a poster boy for advocates and activists fighting to change the perception of how cannabis effects the user. You are not lazy, crazy and suffering from “Reefer Madness” as many people would try and make you believe. Keep dominating in the pool and go USA!

    1 2653

    There is a lot more to cannabis than people think. As legalization spreads, there are much more people smoking marijuana. These people assume that there is just marijuana to smoke, but that is not the case. Cannabis strains fall into three categories: Sativa, Indica, and hybrids. Let’s look at the three and their differences. These three strands are broken into three colors: purple, maroon, and green.

    The purple stand for the Indica, the maroon stands for the Sativa, and the green represents the hybrid. The first main difference comes in the effects. For instance, Indica is usually known for being more relaxing and having an effect on the full-body. On the other hand, Sativa usually lifts you up and provokes creativity. Because of this difference, most people tend to look out for Sativa during the day and indica during the nighttime.

    There are also difference medicinal benefits. Indica typically helps people that have insomnia or are suffering from some type of pain. On the other hand, Sativa is used for people suffering from depression, fatigue, or even ADD. Why are these differences there? Well, these differences exist because of the origins of the plants.

    Indica plants are usually shorter and bushier and are found in rougher climates such as mountains. In addition, they also have higher resin production. Indicas are great for indoor cultivation for these reasons as well as shorter flowering time. Sativa is taller, take longer to grow, and survive in warmer climates. That’s why they are best found outdoors.

    But what about hybrids? Hybrids can have various effects since it is a mixture of both Indica and sSativa. Some cultivators are even able to mix the two together and have the exact impact that a consumer may want or need. For instance, a hybrid can make you both relaxed and creative. Now, if you are ever looking to buy legal marijuana, you can know the differences and what you are going to experience.

    1 2008

     

    It Could Be Time to Revisit An Old Favorite

    We’ve been watching an old favorite of ours for the last few days and the market seems to be holding a VERY nice looking support level right now. It could be time to start picking back up on this company and just to give you an idea, the last time we began watching this one, it ended up being one of the biggest winners we’ve seen in the MJ space to date.

    We normally don’t do “alerts” but this one could be worth a closer look sooner than later. Stay tuned.

    0 1707

     

    Another wide based weed study published by two Norwegian analysts a week ago and distributed in the online journal Addiction suggests that cannabis may not be as unsafe as initially accepted with regards to working a vehicle. The scientists had one basic thing as their top priority: dissect to what degree intense cannabis inebriation improves the probability of a vehicle crash. To do this, they inspected two separate studies.

    The primary study recreated two beforehand distributed meta-examinations (studies that take a gander at numerous different studies under one umbrella), however, expected to remedy methodological inadequacies. This incorporated a gathering of about 51,000 individuals, of which around 23,000 were controls and the rest of cannabis inebriation case illustrations, and a second specimen size of more than 93,000 cases, of which very nearly 89,000 were controls.

    Study two was a modified meta-examination that included 28 estimates from 21 observational studies. Everything considered, study two incorporated a specimen tally that just about hit 240,000. Their discoveries demonstrated that earlier studies neglected to appropriately represent certain “known confounders,” for example, age and sexual orientation, subsequently skewing the outcomes. Taking after alterations that were not connected to past studies, scientists established that driving after smoking prompted an improve in accident probability at a component of 1.2 to 1.4.

    In plainer terms, it was a huge expansion of low-to-moderate extents, which is a huge difference between earlier study discoveries. Similarly, liquor improved the probability of an engine vehicle crash by a variable of very nearly four. This study could be especially essential for supporters of pot development since it’s substantial, speaks to various and huge numbers of cases, and inspects information over more than a three-decade period (1982 through 2015). At the end of the day, it could be translated as to a great extent illustrative of the worldwide populace.

    0 2279

    CHEYENNE, WY / ACCESSWIRE / February 1, 2016 / FBEC Worldwide, Inc. (FBEC), a beverage company with intellectual property formulas and marketing capability for the production and distribution of proprietary beverages, is pleased to announce that as of today, Monday 2/1/2016, FBEC has completed and signed a Board of Directors resolution, Pre14C & Written Consent of Shareholders for the reduction in FBEC’s authorized shares from 5 billion to 2.2 billion.

    “This has been a long time coming. There are a lot of moving parts and I am very proud to announce that the process to reduce the authorized shares in an effort to clean up our capital structure is in motion and moving ahead full steam,” said CEO Jason Spatafora.

    About FBEC Worldwide, Inc.

    FBEC Worldwide is an innovative beverage company dedicated to offering proprietary products focused towards significant target markets, both domestic and abroad. We are committed to increasing our market size and scope through the optics of creative marketing and most importantly customer satisfaction. Our growth strategies will focus on a number of major initiatives including, unique branding opportunities that will be targeted at key demographic groups, and to develop strong community and distributor relationships.

    As we look ahead, FBEC Worldwide will develop and build name brands focused on strong rates of growth within key fundamental consumer groups. Our company is dedicated to becoming a leading developer of name brand beverage alternatives geared specifically towards large, significantly important demographics within major markets.

    Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The Company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

    Contact:

    Investors:

    Joe Sirianni
    MIDAM Ventures LLC
    (305) 707-7018
    jsirianni@MidamIr.com
    www.MIDAMIr.com
    SOURCE: FBEC Worldwide, Inc.

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements